loratadine has been researched along with naltrexone in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (83.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carrupt, PA; Crivori, P; Cruciani, G; Testa, B | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bu, H; Chen, YL; Halls, TD; Jiang, X; Naidong, W; Shou, WZ | 1 |
| Clèdes, J; Legroux-Crespel, E; Misery, L | 1 |
1 review(s) available for loratadine and naltrexone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for loratadine and naltrexone
| Article | Year |
|---|---|
A comparative study on the effects of naltrexone and loratadine on uremic pruritus.
Topics: Antipruritics; Drug Administration Schedule; Female; Humans; Loratadine; Male; Middle Aged; Naltrexone; Pruritus; Surveys and Questionnaires; Treatment Outcome; Uremia | 2004 |
4 other study(ies) available for loratadine and naltrexone
| Article | Year |
|---|---|
Predicting blood-brain barrier permeation from three-dimensional molecular structure.
Topics: Blood-Brain Barrier; Databases, Factual; Models, Chemical; Molecular Conformation; Multivariate Analysis; Permeability; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Simultaneous development of six LC-MS-MS methods for the determination of multiple analytes in human plasma.
Topics: Albuterol; Chromatography, Liquid; Clonidine; Fentanyl; Humans; Loratadine; Mass Spectrometry; Naltrexone; Pharmaceutical Preparations; Ritonavir; Technology, Pharmaceutical | 2002 |